A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCTID	NCT06164730 (View at clinicaltrials.gov)
Description	VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population. (Show More)
Development Status	Active
Indication	Heterozygous Familial Hypercholesterolemia, Premature Coronary Heart Disease
Disease Ontology Term	DOID:13810
Compound Name	VERVE-102
Sponsor	Verve Therapeutics, Inc.
Funder Type	Industry
Recruitment Status	Recruiting (Click here for study contact information)
Enrollment Count	85 (ESTIMATED)
Results Posted	Not Available

Eligible Age	18 Years - 70 Years
Standard Ages	Adult, Older adult
Sexes Eligible for Study	ALL
Eligibility Criteria	Inclusion Criteria: * Diagnosis of HeFH or premature CAD Exclusion Criteria: * Homozygous familial hypercholesterolemia * Active or history of chronic liver disease * Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe * Clinically significant or abnormal laboratory values as defined by the protocol View Inclusion and Exclusion Criteria at ClinicalTrials.gov

No.of Trial Sites 🔄	21
Locations	New Zealand,Canada,United States,United Kingdom,Israel,Australia

Has US IND	True
FDA Designations	Fast Track
Recent Updates	Verve was acquired by Lilly in June 2025